Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection
Galan et al.,
Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe..,
Pathogens and Global Health, doi:10.1080/20477724.2021.1890887
RCT 168 very late stage severe condition hospitalized patients comparing CQ, HCQ, and ivermectin not showing significant differences. Authors were unable to add a control arm due to ethical issues.
Authors claim that "the mortality rates of the three groups are very similar to historical reports of other studies that used placebo in hospitalized patients", without providing any reference. However
[sciencedirect.com] shows 43% hospital mortality in the northern region of Brazil, where the study was performed, from which we can estimate the mortality with ivermectin in this study is 47% lower, RR 0.53. Further, the study is restricted to more severe cases, hence the expected mortality may be higher.
Galan et al., 8 Mar 2021, peer-reviewed, 19 authors.
Abstract: Pathogens and Global Health
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ypgh20
Phase 2 randomized study on chloroquine,
hydroxychloroquine or ivermectin in hospitalized
patients with severe manifestations of SARS-CoV-2
infection
Luis Enrique Bermejo Galan, Nayara Melo dos Santos, Mauro Shosuka Asato,
Jucineide Vieira Araújo, Adriana de Lima Moreira, Aléxia Mahara Marques
Araújo, Artur Diogenes Pinheiro Paiva, Diego Guilherme Santos Portella,
Frank Silas Saldanha Marques, Gabriel Melo Alexandre Silva, Joana de Sousa
Resende, Marycassiely Rodrigues Tizolim, Poliana Lucenados Santos, Steffi
Ferreira Buttenbender, Stephanye Batista de Andrade, Roberto Carlos Cruz
Carbonell, Juliana Gomes Da Rocha, Ruy Guilherme Silveira de Souza & Allex
Jardim da Fonseca
To cite this article: Luis Enrique Bermejo Galan, Nayara Melo dos Santos, Mauro Shosuka
Asato, Jucineide Vieira Araújo, Adriana de Lima Moreira, Aléxia Mahara Marques Araújo, Artur
Diogenes Pinheiro Paiva, Diego Guilherme Santos Portella, Frank Silas Saldanha Marques,
Gabriel Melo Alexandre Silva, Joana de Sousa Resende, Marycassiely Rodrigues Tizolim, Poliana
Lucenados Santos, Steffi Ferreira Buttenbender, Stephanye Batista de Andrade, Roberto Carlos
Cruz Carbonell, Juliana Gomes Da Rocha, Ruy Guilherme Silveira de Souza & Allex Jardim da
Fonseca (2021) Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in
hospitalized patients with severe manifestations of SARS-CoV-2 infection, Pathogens and Global
Health, 115:4, 235-242, DOI: 10.1080/20477724.2021.1890887
To link to this article: https://doi.org/10.1080/20477724.2021.1890887
Published online: 08 Mar 2021.
Submit your article to this journal
Article views: 14709
View related articles
View Crossmark data
Citing articles: 1 View citing articles
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=ypgh20
PATHOGENS AND GLOBAL HEALTH
2021, VOL. 115, NO. 4, 235–242
https://doi.org/10.1080/20477724.2021.1890887
ARTICLE
Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin
in hospitalized patients with severe manifestations of SARS-CoV-2 infection
Luis Enrique Bermejo Galan a,b, Nayara Melo dos Santos a, Mauro Shosuka Asato a,
Jucineide Vieira Araújo a,b, Adriana de Lima Moreira b, Aléxia Mahara Marques Araújo b,
Artur Diogenes Pinheiro Paiva b, Diego Guilherme Santos Portella b, Frank Silas Saldanha Marques
Gabriel Melo Alexandre Silva b, Joana de Sousa Resende b, Marycassiely Rodrigues Tizolim b,
Poliana Lucenados Santos b, Steffi Ferreira Buttenbender b, Stephanye Batista de Andrade b,
Roberto Carlos Cruz Carbonell a,b, Juliana Gomes Da Rocha c, Ruy Guilherme Silveira de Souza b
and Allex Jardim da Fonseca a,b,c
b
,
a
Department of Infectious Diseases of Hospital Geral De Roraima. Universidade Federal De Roraima. Boa Vista Brazil; bPost Graduate
Program in Health Science of Universidade Federal De Roraima, Health Science Center, Boa Vista, Brazil; cClinical Research Center of the
Oncological Center of Roraima - Boa Vista - Brazil
ABSTRACT
KEYWORDS
Objective: Given the urgent need for strategies to minimize the damage caused by this
pandemic, this study performed a randomized, double-blind phase 2 study to assess the safety
of the effectiveness of chloroquine (CQ), hydroxychloroquine (HCQ) or ivermectin in severe
forms of COVID-19, in addition to identifying predictors of mortality in..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit